Supernus Pharmaceuticals Share Holder Equity 2011-2024 | SUPN
Supernus Pharmaceuticals share holder equity from 2011 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Supernus Pharmaceuticals Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$922 |
| 2022 |
$886 |
| 2021 |
$816 |
| 2020 |
$745 |
| 2019 |
$595 |
| 2018 |
$453 |
| 2017 |
$267 |
| 2016 |
$192 |
| 2015 |
$88 |
| 2014 |
$41 |
| 2013 |
$33 |
| 2012 |
$58 |
| 2011 |
$9 |
| 2010 |
$0 |
Supernus Pharmaceuticals Quarterly Share Holder Equity
(Millions of US $) |
| 2024-09-30 |
$1,007 |
| 2024-06-30 |
$957 |
| 2024-03-31 |
$929 |
| 2023-12-31 |
$922 |
| 2023-09-30 |
$912 |
| 2023-06-30 |
$920 |
| 2023-03-31 |
$912 |
| 2022-12-31 |
$886 |
| 2022-09-30 |
$853 |
| 2022-06-30 |
$841 |
| 2022-03-31 |
$828 |
| 2021-12-31 |
$816 |
| 2021-09-30 |
$810 |
| 2021-06-30 |
$786 |
| 2021-03-31 |
$754 |
| 2020-12-31 |
$745 |
| 2020-09-30 |
$709 |
| 2020-06-30 |
$666 |
| 2020-03-31 |
$613 |
| 2019-12-31 |
$595 |
| 2019-09-30 |
$557 |
| 2019-06-30 |
$523 |
| 2019-03-31 |
$480 |
| 2018-12-31 |
$453 |
| 2018-09-30 |
$422 |
| 2018-06-30 |
$390 |
| 2018-03-31 |
$352 |
| 2017-12-31 |
$267 |
| 2017-09-30 |
$252 |
| 2017-06-30 |
$229 |
| 2017-03-31 |
$206 |
| 2016-12-31 |
$192 |
| 2016-09-30 |
$173 |
| 2016-06-30 |
$110 |
| 2016-03-31 |
$97 |
| 2015-12-31 |
$88 |
| 2015-09-30 |
$79 |
| 2015-06-30 |
$72 |
| 2015-03-31 |
$64 |
| 2014-12-31 |
$41 |
| 2014-09-30 |
$36 |
| 2014-06-30 |
$33 |
| 2014-03-31 |
$29 |
| 2013-12-31 |
$33 |
| 2013-09-30 |
$12 |
| 2013-06-30 |
$36 |
| 2013-03-31 |
$41 |
| 2012-12-31 |
$58 |
| 2012-09-30 |
$25 |
| 2012-06-30 |
$38 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$9 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$0 |
| 2011-03-31 |
$0 |
| 2010-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.000B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
